Fourth study published over two-year span that analyzes key leukemia protein
Northwestern Medicine scientists have discovered two successful therapies that slowed the progression of pediatric leukemia in mice, according to three studies published over the last two years in the journal Cell, and the final paper published Dec. 20 in Genes & Development.
When a key protein responsible for leukemia, MLL, is stabilized, it slows the progression of the leukemia, the most recent study found. The next step will be to combine the treatments from the past two years of research into a pediatric leukemia “super drug” to test on humans in a clinical trial.
The survival rate is only 30 percent for children diagnosed with MLL-translocation leukemia, a cancer that affects the blood and bone marrow. Patients with leukemia have a very low percentage of red blood cells, making them anemic, and have approximately 80 times more white blood cells than people without cancer.
30%Current survival rate for pediatric leukemia patients.
“These white blood cells infiltrate many of the tissues and organs of the affected individuals and is a major cause of death in leukemia patients,” said senior author Ali Shilatifard, the Robert Francis Furchgott Professor of Biochemistry and Molecular Genetics and Pediatrics, the chairman of biochemistry and molecular genetics and the director of Northwestern’s Simpson Querrey Center for Epigenetics. “This is a monster cancer that we’ve been dealing with for many years in children.”
There are several types of leukemia. This research focused on the two most common found in infants through teenagers: acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).
For the past 25 years, Shilatifard’s laboratory has been studying the molecular function of MLL within its complex known as COMPASS (Complex Proteins Associated with Set1). Most recently, it was demonstrated that COMPASS components are one of the most frequently identified mutations in cancer.The next step of this work will be to bring the drug to a clinical trial setting, which Shilatifard said he hopes will happen in the next three to five years.
“I’ve been working on this translocation for more than two decades, and we’re finally at the point where in five to 10 years, we can get a drug in kids that can be effective,” Shilatifard said. “If we can bring that survival rate up to 85 percent, that’s a major accomplishment.”
Earlier work from Shilatifard’s laboratory published in Cell in 2018 identified compounds that could slow cancer growth by interrupting a gene transcription process known as “Super Elongation Complex” (SEC). It was the first compound in its class to do this.
This MLL stabilization process discovered in the most recent paper could potentially work in cancers with solid tumors, such as breast or prostate cancer, said first author Zibo Zhao, a postdoctoral research fellow in Shilatifard’s lab.
“This opens up a new therapeutic approach not only for leukemia, which is so important for the many children who are diagnosed with this terrible cancer, but also for other types of cancers that plague the population,” Zhao said.
“The publication of these four papers and the possibility of a future human clinical trial could not have happened if it weren’t for the cross-disciplinary collaboration at Northwestern,” Shilatifard said.
Learn more: Pediatric leukemia ‘super drug’ could be developed in the coming years
The Latest on: Pediatric leukemia
[google_news title=”” keyword=”pediatric leukemia” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Pediatric leukemia
- Professional Faqs: How Does Air Pollution Affect Children's Health And Development?on May 9, 2024 at 8:58 pm
VatsDoctor of Medicine (MBBS) · 1.5 years of experience · IndiaAir pollution can have a number of harmful effects on children's health and development, including: Respiratory problems: Air pollution ...
- A New Kid on the Block of Therapy for Acute Myeloid Leukemiaon May 9, 2024 at 5:02 am
Crenolanib may have advantages over other therapies targeting acute myeloid leukemia with FLT3 gene mutations.
- How Long Do You Have To Live With Leukemia? A Review By Doctorson May 7, 2024 at 2:28 pm
Expert opinion from Marcella Abunahman Pereira Specialization in Clinical Cardiology · 12 years of experience · Brazil Leukemia is a cancer that involves the white blood cells which are potent to ...
- Assisted Reproductive Technology Linked to Increased Risk of Leukemiaon May 7, 2024 at 5:30 am
Another study adds to research suggesting that assisted reproductive technology may increase the risk of leukemia in offspring.
- Medically aided conception vs. natural conception: Study explores cancer risk in childrenon May 7, 2024 at 3:29 am
Study: Medically Assisted Reproduction and Risk of Cancer Among Offspring. Image Credit: Antonio Guillem/Shutterstock.com. Background. Childhood cancers are a global health proble ...
- Childhood Leukemia: Causes, symptoms, and treatment of blood canceron May 2, 2024 at 10:30 pm
Leukemia, a major global health challenge, disrupts blood and bone marrow functions, especially in children. It includes subtypes like acute lymphoblastic leukemia and acute myeloid leukemia. Factors ...
- White Hut Holyoke invites patrons to support baby’s recovery from acute myeloid leukemiaon May 2, 2024 at 3:20 pm
HOLYOKE — Ashton Conroy, the son of Holyoke Police Officer Crystal Conroy, is courageously battling acute myeloid leukemia. From Friday through Sunday, White Hut in Holyoke will donate 15% of all ...
- Elise Lampert has leukemia. The Jasper pitcher refused to let it take away softballon May 2, 2024 at 8:05 am
Lampert was diagnosed with chronic myeloid leukemia in December. It won’t be the end of ... She was taken by ambulance to Riley’s Children’s Hospital in Indianapolis. Two days later, the doctors ...
- Fresh and Frozen Embryo Transfers May Increase Risk of Childhood Leukemiaon May 1, 2024 at 9:00 pm
Opens in a new tab or window While overall cancer risk was no different for children born after fertility treatments compared with those naturally conceived, frozen or fresh embryo transfer did appear ...
- Unraveling the roles of non-coding DNA explains childhood cancer's resistance to chemotherapyon May 1, 2024 at 12:16 pm
St. Jude Children's Research Hospital scientists have identified specific DNA variants in the non-coding regions of the genome contributing to chemotherapy resistance in acute lymphoblastic leukemia ...
via Bing News